Sierra Summit Advisors LLC Takes Position in Halozyme Therapeutics, Inc. $HALO

Posted by Francis Steltz on May 22nd, 2026

Sierra Summit Advisors LLC purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) in the 4th quarter, HoldingsChannel.com reports. The firm purchased 12,538 shares of the biopharmaceutical company’s stock, valued at approximately $844,000.

Other large investors have also modified their holdings of the company. Root Financial Partners LLC bought a new stake in shares of Halozyme Therapeutics in the 3rd quarter valued at about $25,000. Larson Financial Group LLC raised its position in shares of Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 343 shares in the last quarter. Clearstead Advisors LLC raised its position in shares of Halozyme Therapeutics by 107.7% in the 3rd quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 265 shares in the last quarter. Penserra Capital Management LLC bought a new position in shares of Halozyme Therapeutics in the 3rd quarter worth $52,000. Finally, Wexford Capital LP bought a new position in shares of Halozyme Therapeutics in the 3rd quarter worth $70,000. Institutional investors own 97.79% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on HALO. Wall Street Zen raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Wells Fargo & Company boosted their price objective on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 19th. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. Morgan Stanley reduced their price objective on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Finally, Benchmark upped their target price on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, February 19th. Seven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $80.67.

Get Our Latest Stock Analysis on Halozyme Therapeutics

Insider Buying and Selling at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $64.24, for a total value of $1,284,800.00. Following the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $49,322,187.20. This represents a 2.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Cortney Caudill sold 20,000 shares of the stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $67.80, for a total value of $1,356,000.00. Following the completion of the transaction, the chief operating officer directly owned 14,366 shares in the company, valued at $974,014.80. This represents a 58.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 120,482 shares of company stock worth $8,200,842. 2.50% of the stock is owned by corporate insiders.

Halozyme Therapeutics Trading Down 0.7%

Shares of Halozyme Therapeutics stock opened at $68.52 on Friday. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81. Halozyme Therapeutics, Inc. has a 12-month low of $51.06 and a 12-month high of $82.22. The firm has a market capitalization of $8.13 billion, a price-to-earnings ratio of 24.65, a PEG ratio of 0.28 and a beta of 0.89. The firm’s 50 day simple moving average is $65.70 and its two-hundred day simple moving average is $68.75.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last issued its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The business had revenue of $376.71 million for the quarter, compared to analyst estimates of $358.60 million. During the same quarter in the prior year, the business posted $1.11 EPS. Halozyme Therapeutics’s revenue for the quarter was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Analysts predict that Halozyme Therapeutics, Inc. will post 7.66 EPS for the current year.

Halozyme Therapeutics Company Profile

(Free Report)

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.